Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics
July 20, 2020 07:45 ET
|
RP Management, LLC
NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. (Nasdaq: PTCT) to acquire a portion of PTC’s royalty interest...
Royalty Pharma Announces Closing of Initial Public Offering
June 18, 2020 16:15 ET
|
RP Management, LLC
NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ: RPRX) today announced the closing of the initial public offering of 89,333,920 shares of its Class A ordinary shares pursuant...
Royalty Pharma Appoints Bonnie Bassler, PhD to the Company’s Board of Directors
June 16, 2020 08:00 ET
|
RP Management, LLC
NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma today announced the appointment of Dr. Bonnie L. Bassler, PhD to the company's Board of Directors, effective immediately. Dr. Bassler is an...
Royalty Pharma Announces Pricing of Initial Public Offering
June 15, 2020 22:15 ET
|
RP Management, LLC
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc today announced the pricing of the initial public offering of 77,681,670 shares of its Class A ordinary shares pursuant to a...
Royalty Pharma Acquires Partial Royalty Interest on Prevymis™ (letermovir) From AiCuris Anti-Infective Cures GmbH
June 09, 2020 08:05 ET
|
RP Management, LLC
NEW YORK and WUPPERTAL, Germany, June 09, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma and AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against...
Royalty Pharma Files Registration Statement for Proposed Initial Public Offering
May 23, 2020 14:02 ET
|
RP Management, LLC
NEW YORK, May 23, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”)...